Celldex Therapeutics, Inc.
https://www.celldex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celldex Therapeutics, Inc.
Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
Pfizer Signs Paxlovid Agreement As China Cases Soar
Pfizer has signed up with a state-owned enterprise for the distribution of its recently approved oral antiviral for COVID-19 in China, where daily case counts are surging amid some tightening restrictions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Avant Immunotherapeutics, Inc.
- CuraGen Corporation
- Kolltan Pharmaceuticals, Inc.
- Xetrios Therapeutics Inc.